A Study to Evaluate the Diagnostic Efficacy of 68Ga- MY6349 PET/CT in Patients With Tumours

NARecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 18, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Tumour of Epithelial Origin68Ga-MY6349
Interventions
DIAGNOSTIC_TEST

68Ga-MY6349 PET/CT Scan

The imaging agent 68Ga-MY6349 used in this project is synthesized following the standards for radiopharmaceutical production, with reference to the Chinese Pharmacopoeia (quality standards for 18F-FDG). The pH value is between 5.0 and 8.0; the radiochemical purity is not less than 95%, and the bacterial endotoxin content in each milliliter of solution is less than 15EU; the radioactive concentration is not less than 37 MBq/mL; the solvent residues comply with the regulations. Specification: 185\~1850 MBq/ml Characteristics: Clear, colorless, no visible particles. Radioactive physical half-life: 68Ga is 68 minutes. Expiry: Calculated from the time of labeling, stable for 3 half-lives. Administration method: Intravenous injection. Dosage: 0.05-0.1mCi/kg, flush with 5 mL of saline after injection.

Trial Locations (1)

Unknown

RECRUITING

Department of Nuclear Medicine,Xijing Hospital, Fourth Military Medical University, Xi'an, China, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER